Brief: Heidelberg Pharma plans capital measure to fund its ATAC development programs

Heidelberg Pharma AG

03/11/2017 11:42

Nov 3 (Reuters) - HEIDELBERG PHARMA AG  WL6G.DE  
    * PLANS CAPITAL MEASURE TO FUND ITS ATAC DEVELOPMENT 
PROGRAMS 
    * NEW SHARES AND CONVERTIBLE BONDS WILL BE OFFERED FOR 
SUBSCRIPTION TO ALL SHAREHOLDERS 
    * PLANS TO INCREASE SHARE CAPITAL FROM EUR 14.97 MILLION BY 
UP TO 
EUR 7.48 MILLION TO UP TO EUR 22.45 MILLION 
    * PLANS TO ISSUE UP TO 14.97 MILLION CONVERTIBLE BONDS WITH 
A 
PRINCIPAL AMOUNT OF EUR 1.00 EACH 
    * SUBSCRIPTION PRICE PER NEW SHARE IS EXPECTED TO BE 
DETERMINED 
ON 16 NOVEMBER 2017 
 
Source text for Eikon:  ID:nEQ27jxt1a  
Further company coverage:  WL6G.DE  
 
 (Gdynia Newsroom) 
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))